SOURCE: LifeSci Advisors

LifeSci Advisors

November 13, 2013 08:00 ET

LifeSci Advisors Initiates Coverage of NeoStem, Inc.

NEW YORK, NY--(Marketwired - Nov 13, 2013) - LifeSci Advisors, LLC

  • Phase II Data from Acute Myocardial Infarction Program Expected in 2014

  • Core Cell Therapy Contract Development and Manufacturing Business

  • Report Available for Download at http://lifesciadvisors.com/clients/neostem/

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of NeoStem, Inc. (NASDAQ: NBS), a leader in cell therapy developing potentially transformative treatments for patients in several indications. NeoStem operates four subsidiaries with a core competency in the cell therapy and regeneration space, including a successful contract development and manufacturing business. The Company's lead program, AMR-001, is being tested in a Phase II clinical trial (PreSERVE) in patients with acute myocardial infarction, with potential applications in other ischemic diseases such as congestive heart failure and traumatic brain injury. AMR-001 is an autologous cell therapy derived from a patient's own bone marrow, and homes to the site of ischemia to rebuild vasculature and prevent damaging ventricular remodeling. A Phase I clinical trial demonstrated increased cardiac perfusion in patients who received 10 million or more cells, and Phase 2 data from PreSERVE are expected in the third quarter of 2014.

"NeoStem has developed an impressive set of cell therapy programs targeting indications with great market potential such as acute myocardial infarction," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The PCT contract and manufacturing business along with key scientific partnerships put NeoStem at the leading edge of the regenerative medicine industry."

NeoStem's Amorcyte subsidiary is developing a regulatory T cell (Treg) therapy in collaboration with leading experts at the University of California San Francisco. Tregs help maintain immune balance and are applicable for many immune-mediated and autoimmune diseases. A Phase II trial is expected to launch in 2014 in type 1 diabetes patients, and a Phase Ib/IIa program is currently being developed for steroid resistant asthma to launch in the second half of 2014. NeoStem's cell therapy contract and development manufacturing business, Progenitor Cell Therapy (PCT), serves clients in the regenerative medicine industry, and gives NeoStem multiple paths to future revenue. The Company's VSEL™ technology is an adult stem cell platform applicable to many disease areas. 

In a 54 page Initiation Report by LifeSci Advisors, we explain the clinical development plans for NeoStem's programs. The report discusses the advantages of lead program AMR-001 and how those advantages position the therapy within the competitive landscape. We highlight NeoStem's academic collaborations to bring regulatory T cell therapies into the clinic, the risk reduction aspect of PCT, and promising preclinical research with VSEL™ technology.

Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:

LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's research and development and clinical evaluation efforts towards commercialization of cellular therapies, including with respect to AMR-001, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the Company's ability to successfully grow its contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Contact Information